[{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fedratinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Oncology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMS-986393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Celgene Corporation"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CC-97540","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Celgene Corporation \/ Celgene Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Celgene Corporation

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Celgene Corporation

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 1094 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

5 All APIs, 2 USDMF, 1 KDMF, 2 NDC API

DEVELOPMENTS

154 Drugs in Development

154 Drugs in Development

FINISHED DOSAGE FORMULATIONS

52 FDF Dossiers, 8 FDA Orange Book, 44 Europe

INSPECTIONS & REGISTRATIONS

15 FDA, 1 EDQM

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

02

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

03

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

04

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

05

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

06

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

07

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

08

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

09

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed

10

Celgene Corporation

U.S.A

Biotech Week Boston

Not Confirmed